Buckley Wealth Management LLC Has $1.07 Million Holdings in Medtronic plc (NYSE:MDT)

Buckley Wealth Management LLC boosted its position in shares of Medtronic plc (NYSE:MDT) by 46.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,115 shares of the medical technology company’s stock after buying an additional 3,860 shares during the period. Buckley Wealth Management LLC’s holdings in Medtronic were worth $1,067,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Stokes Capital Advisors LLC grew its stake in Medtronic by 1.3% during the second quarter. Stokes Capital Advisors LLC now owns 42,388 shares of the medical technology company’s stock worth $3,734,000 after buying an additional 564 shares in the last quarter. Hurlow Wealth Management Group Inc. grew its stake in Medtronic by 13.4% during the second quarter. Hurlow Wealth Management Group Inc. now owns 3,383 shares of the medical technology company’s stock worth $298,000 after buying an additional 400 shares in the last quarter. 180 Wealth Advisors LLC grew its stake in Medtronic by 5.7% during the second quarter. 180 Wealth Advisors LLC now owns 24,213 shares of the medical technology company’s stock worth $2,110,000 after buying an additional 1,296 shares in the last quarter. Thrive Wealth Management LLC acquired a new stake in shares of Medtronic in the 2nd quarter valued at approximately $347,000. Finally, Tlwm boosted its stake in shares of Medtronic by 2.6% in the 2nd quarter. Tlwm now owns 8,533 shares of the medical technology company’s stock valued at $752,000 after purchasing an additional 215 shares in the last quarter. 80.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medtronic

In other news, EVP Gregory L. Smith sold 10,000 shares of Medtronic stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $83.84, for a total transaction of $838,400.00. Following the sale, the executive vice president now directly owns 46,723 shares in the company, valued at approximately $3,917,256.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Brett A. Wall sold 1,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $83.38, for a total value of $83,380.00. Following the sale, the executive vice president now directly owns 33,573 shares in the company, valued at approximately $2,799,316.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregory L. Smith sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $83.84, for a total value of $838,400.00. Following the completion of the sale, the executive vice president now owns 46,723 shares in the company, valued at $3,917,256.32. The disclosure for this sale can be found here. Insiders have sold 19,866 shares of company stock worth $1,688,839 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of Medtronic from $92.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 22nd. Wells Fargo & Company raised their price objective on shares of Medtronic from $100.00 to $102.00 and gave the company an “overweight” rating in a report on Wednesday, August 23rd. CL King started coverage on shares of Medtronic in a report on Friday, June 30th. They set a “buy” rating and a $106.00 price target for the company. Robert W. Baird began coverage on shares of Medtronic in a report on Tuesday, July 18th. They set a “neutral” rating and a $90.00 price target for the company. Finally, 22nd Century Group reaffirmed an “initiates” rating on shares of Medtronic in a research report on Friday, June 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $91.67.

Medtronic Stock Up 1.4 %

MDT traded up $1.17 during mid-day trading on Monday, reaching $82.94. 1,934,399 shares of the stock were exchanged, compared to its average volume of 5,677,964. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.79 and a current ratio of 2.42. The stock has a market capitalization of $110.35 billion, a PE ratio of 30.69, a price-to-earnings-growth ratio of 2.88 and a beta of 0.71. The company has a 50 day moving average price of $84.16 and a two-hundred day moving average price of $84.35. Medtronic plc has a 1 year low of $75.76 and a 1 year high of $92.02.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, August 22nd. The medical technology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.09. The firm had revenue of $7.70 billion for the quarter, compared to the consensus estimate of $7.57 billion. Medtronic had a net margin of 11.47% and a return on equity of 13.81%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.13 EPS. As a group, research analysts anticipate that Medtronic plc will post 5.12 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 22nd will be paid a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Thursday, September 21st. Medtronic’s payout ratio is 101.85%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.